Through the partnership Medtronic will leverage Apollo’s clinical insight to develop a mobile, low-cost system for treating patients with end stage renal disease, the companies said. The medtech giant plans to invest more than $25 million (150 core rupees) to develop and manufacture the systems in India.
"Specifically, the collaboration seeks improved accessibility, outcomes, affordability, operational ease, and environmental protection while providing hemodialysis services to ESRD patients requiring RRT," according to a press release. "For the 1st time, Medtronic is establishing an India R&D team that will focus on design, development and manufacturing of key components of the system in India."
The companies expect to launch the hemodialysis system in 2016.